Life Sciences Validation, Calibration Market to See 6.7% Annual Growth Through 2023
Strong Demand from the Pharma and Biotech Markets Boosting Industry Expansion
May 02, 2019
WELLESLEY, Mass., May 02, 2019–Strong demand from the pharma and biotech markets and the rise in software for calibration management are factors helping to drive growth of validation, calibration and standardization for the life sciences industry, according to a report by BCC Research, “Validation, Calibration and Standardization in the Life Sciences Market.”
The market expects a compound annual growth rate (CAGR) of 6.7% through 2023, when it could be worth $2.1 billion.
Major players in the market include Thermo Fisher Scientific (TMO), Data Science International, Merck (MRK), Evolution Scientific and Beckman Coulter.
Research Highlights
- End-user growth will be strongest among pharmaceutical and biotechnology companies, which expect a CAGR through 2023 of 7.1%, followed by contract research organizations at 6.8% and research laboratories at 6.4%.
- North America leads the market by size, with a 2018 value of $606.2 million, followed by the Asia-Pacific region at $393.2 million and Europe at 358.9 million.
- Consumables lead the market by growth, with a CAGR through 2023 of 6.5%, followed by instruments at 6.3%.
“The rising adoption of software for calibration management is also driving the utilization of services by pharmaceutical and biotechnology companies and other research organizations that reduce the overall time and cost of validation and calibration processes,” notes report author Sathya Durga. “Software usage ensures that the calibration performed at multiple places remains the same and on time. This helps companies maintain accuracy and quality and reduce errors.”
Strong Growth Coming from the Pharma and Biotech Market
The market is being driven in particular by surging demand from the pharma and biotech sectors. These fields need precisely-calibrated equipment to ensure product quality and accurate process measurements, which further emphasizes the need for instrument validation, both to ensure internal standards and to meet stringent regulations. Regulations pertaining to calibration, validation and standardization will create a broad pool of opportunities for the adoption of calibration services.
Editors/reporters requesting analyst interviews should contact Sarah Greenberg at press@bccresearch.com.
Validation, Calibration and Standardization in the Life Sciences Market( BIO179A )
Publish Date: Apr 2019
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.
BCC Library Membership Benefits
Unlimited Access to Market Research Reports for Academic Institutions and Corporations.
Custom Research
Tailored solutions across industries for your unique business needs.
More in Cell Biology
- Biomarker Deals Accelerate: Strategic Alliances Reshape Life Sciences Innovation
- China’s DNA Sequencing Market to Grow at 21.5% CAGR by 2030
- mRNA Market Forecast: Small Decline of -0.04% CAGR by 2030
- Molecular Diagnostics Market to Grow at 13.1% CAGR Through 2030
- Biotech Equipment Market Projected to Reach $143.9 Billion Globally by 2030
Reports from Cell Biology
Recent News
- Global Hyaluronic Acid in Healthcare Market to Reach $10.5 Billion by 2030
- Global Patient Monitoring Market to Reach $55.8 Billion by End of 2030
- Global Market for Biological and Medical Imaging Reagents Set to Surge to $40.1 Billion by 2030
- Targeted Alpha Therapies Market to Grow at 44% CAGR Globally by 2030
- Global Anti-Parkinson's Drugs Markets Projected to Reach $9.2 Billion by the End of 2030
